ArticleJournal of Huntington's disease2018
Age at Death and Causes of Death in Patients with Huntington Disease in Norway in 1986-2015.
Article in Journal of Huntington's disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Accidental Falls in Patients with Hyperkinetic Movement Disorders: A Systematic Review.Tremor and other hyperkinetic movements (New York, N.Y.) · 2022Pooled it
- Effects of time-restricted eating in early-stage Huntington's disease: a pilot study.Nature metabolism · 2026Article
- Epidemiology and economic burden of selected rare genetic diseases in Germany - a claims database study.Orphanet journal of rare diseases · 2025Article
- Metabolomics: a new frontier in neurodegenerative disease biomarker discovery.Metabolomics : Official journal of the Metabolomic Society · 2025Review
- Exploring Place of Death among Individuals with Huntington's Disease in the United States.Journal of the American Medical Directors Association · 2025Article
- Time-restricted eating in early-stage Huntington's disease: A 12-week interventional clinical trial protocol.PloS one · 2025Article
- Data-driven Huntington's disease progression modelling and estimation of societal cost in the UK.Royal Society open science · 2024Article
- Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model.CNS neuroscience & therapeutics · 2024Article
- Risk Factors and Interventions for Suicide in Huntington's Disease-A Systematic Review.Journal of clinical medicine · 2024Review
- Influence of dietary patterns in the pathophysiology of Huntington's Disease: A literature review.AIMS neuroscience · 2024Review
- Palliative care in advanced Huntington's disease: a scoping review.BMC palliative care · 2023Article
- Survival in Huntington's disease and other young-onset dementias.International journal of geriatric psychiatry · 2023Article
- Recent Advances in the Roles of MicroRNA and MicroRNA-Based Diagnosis in Neurodegenerative Diseases.Biosensors · 2022Review
- Hospital Admissions of Huntington's Disease Patients in a Huntington's Disease Centre Between 2011 and 2016: A Retrospective Analysis.Movement disorders clinical practice · 2022Article
- Racial-ethnic inequities in age at death among adults with/without intellectual and developmental disability in the United States.Preventive medicine · 2022Article
- Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach.Frontiers in neurology · 2022Article
- Effects of Percutaneous Endoscopic Gastrostomy in Patients With Huntington Disease.Neurology. Clinical practice · 2021Article
- Incidence of completed suicide and suicide attempts in a global prospective study of Huntington's disease.BJPsych open · 2021Article
- The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington's disease.Journal of biomedical science · 2021Review
- Random Lasing Detection of Mutant Huntingtin Expression in Cells.Sensors (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe literature offers discrepant findings regarding age at death in individuals with Huntington disease (HD).
objectiveTo study the age at death and causes of death in males and females with a diagnosis of HD in Norway.
methodsRegistry study of deaths in 1986-2015 using data from two national registries: the Norwegian Cause of Death Registry (NCDR) and the registry of the Centre for Rare Disorders (CRD), Oslo University Hospital.
resultsMean age at death for individuals with HD was found to be 63.9 years (NCDR) and 61.7 years (CRD), compared to a mean of 76.9 years in the general population (NCDR). There were no significant gender differences for age at death in individuals with HD. The significant increase in age at death within the general population from 1986 to 2015 was not observed in individuals with HD. In 73.5% of individuals with HD, the underlying cause of death was HD, followed by cardiovascular diseases, cancer and respiratory diseases. The most common immediate cause of death was respiratory diseases (44.2%). Suicide was a more common cause of death in the population with HD (2.3%) compared to the general population (1.3%).
conclusionThe age at death of individuals with HD was stable over a period of 30 years and 13.3 years lower than in the general population. Longer life expectancy for females from the general population was not found in females with HD. Suicide was more common among individuals with HD compared to the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.